Yüklüyor......
Natalizumab: Perspectives from the Bench to Bedside
Probably no other disease-modifying drug for multiple sclerosis has a more fascinating story than natalizumab from both the bench to bedside perspective and the postmarketing experience standpoint. Natalizumab is a monoclonal antibody that inhibits the trafficking of lymphocytes from the blood into...
Kaydedildi:
| Yayımlandı: | Cold Spring Harb Perspect Med |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Cold Spring Harbor Laboratory Press
2018
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6280713/ https://ncbi.nlm.nih.gov/pubmed/29500304 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/cshperspect.a029066 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|